No other meeting provides as much information about how the science of pulmonary, critical care, and sleep medicine is changing clinical practice.

LEARN FROM THE BEST. International experts present the latest findings at symposia, year in review sessions, and postgraduate courses.

EXPLORE THE LATEST. With more than 500 sessions and nearly 6,000 research abstracts and case reports expected, ATS 2015 attendees can learn about advances in many fields or focus on specific interests.

NETWORK. The most dedicated clinicians and researchers from Europe and around the world will attend ATS 2015 to exchange ideas in a collegial environment.

NEW WAYS TO LEARN. ATS 2015 will feature adult and pediatric core curriculums, hands-on learning, and the new ATS Discoveries Series with lectures by ground-breaking clinician scientists.

SESSIONS OF PARTICULAR INTEREST
- Differentiating Virus-Driven from Host Defense Immune Responses in Acute Viral-Induced Childhood Asthma
- Scar-Cinomas: The Shared Biology and Clinical Overlap of Fibrosis and Cancer
- How to Cure a Lung Disease: The Cystic Fibrosis Story
- Controversies in Lung Cancer Screening
- How Pathogens Evade Immune Defenses and How We Can Fight Back
- Air Pollution: A Major Global Threat to Lung Health
- Personalized Medicine for Sleep Apnea
- Can We Answer Big Questions in Critical Care with Big Data?
- Endothelium Under Attack: Understanding Pulmonary Vascular Responses to Disease
- Scientific Breakthroughs of the Year: Host Pathogen Interactions and Host Defense
- Development of Pulmonary Disease in Obesity: The Interface Between Metabolism, Microbiome, and Immunity
- Strategies to Address Pediatric Asthma Disparities Through Care Coordination
- Impact of Sleep-Disordered Breathing on Maternal and Fetal Outcomes of Pregnancy
- Translating COPD Discoveries to the Clinic
- Evolving Pathogens: Ebola and Respiratory Enteroviruses

“A rewarding aspect of the ATS International Conference is that it links the world’s best basic and clinical research with real-world practice.”

–Peter J. Sterk, MD, PhD
Professor
University of Amsterdam

Registration now open.
Learn more at conference.thoracic.org/2015
Submission
Manuscripts written in English should be submitted using the online submission website at:

www.karger.com/res

Should you experience any problems with your submission, please contact:

res@karger.com

S. KARGER AG
Editorial Office ‘Respiration’
PO Box
CH–4009 Basel (Switzerland)

All manuscripts must be accompanied by a covering letter signed by all authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. The preferred word processing package is Word for Windows. Presentation of manuscripts should conform with the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (see N Engl J Med 1997;336:309–315).

Conditions
All manuscripts are subject to an editorial process involving the Editor-in-Chief, an Associate Editor and reviewers. Notification can be expected within two months from the date of receipt. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Respiration and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Clinical Trials: In accordance with the recommendations of the International Committee of Medical Journal Editors, the journal requires that all clinical trials having commenced on or after 1 July 2005 be registered in a public trial registry accessible free of charge. Please consult http://www.icmje.org/index.html#clin_trials for further details. Respiration has implemented the expanded definition stating that ‘any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes’. Health-related interventions include any intervention used to modify a biomedical or health-related outcome (for example, drugs, surgical procedures, devices, behavioral treatments, dietary interventions, and process-of-care changes). Health outcomes include any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events. Purely observational studies (those in which the assignment of the medical intervention is not at the discretion of the investigator) will not require registration.

The journal consists of the following sections:

1. Thematic Review Series
2. Editorial Comments
3. Clinical Investigations
4. Interventional Pulmonology
5. Basic Science Investigations
6. The Eye Catcher
7. Novel Insights from Clinical Practice
8. What Is Your Diagnosis?
9. Reviews
10. Guidelines
11. Clinico-Pathological Conferences
12. Letters to the Editor

Reviews: Invited reviews, if accepted, are not subject to page charges. Unsolicited reviews may also be submitted for consideration.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in respiratory medicine are also welcome. Letters to the Editor should be no longer than one printed page.

Eye Catchers: Maximum 1 printed page. Text may not exceed 250 words to allow sufficient space for pictorial material, which is the main object of an Eye Catcher. Maximum 2 references and 2–5 keywords.

Novel Insights from Clinical Practice (formerly Case Reports): Maximum 7 authors. The publication space available for case reports is very limited. The journal only considers case reports with significant new insights or with an extremely unusual and memorable course. Highlighted boxes containing one or two bullet points on ‘Established facts’ (what is already known) and ‘Novel insights’ (what new information has been gained) are required and should be placed on the first page of the report. These should be selected so as to reinforce the novelty of the clinical observation. The text per page should be limited to 1–2 very short sentences. The manuscript should be presented with an abstract (unstructured, max. 200 words), followed by introduction, case report and discussion. Maximum 5 figures.

What Is Your Diagnosis?: Select catchy title not disclosing the diagnosis. Page 1: Case report and 1–2 illustrations and the question ‘What Is Your Diagnosis’ Page 2: The diagnosis followed by a short description of what diagnostic procedures were done to reach the diagnosis and the discussion with references. Maximum 15 references and include 3–5 key words.

Guidelines: Consensus Guidelines are welcome from working groups to provide guidance in key and emerging areas in all fields of respiratory medicine. Such guidelines are also subject to a reviewing process.

Patient Consent: This is required for ALL articles containing personal information about the patient submitted for publication in the following sections: Novel Insights from Clinical Practice What Is Your Diagnosis? Eye Catcher

Signed patient consent must be obtained from the patient, guardian or next of kin (or a statement that the patient was not alive at the time of writing) and submitted along with the manuscript. For Patient Consent Form see www.karger.com/res_Guidelines

Arrangement
Pages should be numbered throughout the manuscript text.

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full words: Abstract Each paper needs an abstract of up to 250 words. Abstracts of papers submitted for publication in the sections Clinical Investigations, Basic Science Investigations, Interventional Pulmonology, and Technical Notes should be structured as follows:

Background: What is the major motive that prompted the study?
Objectives: What is the purpose of the study?
Methods: How was the study done?
Results: Most important findings.
Conclusions: Most important conclusions.

Introduction
What is the main question? State your considerations leading to the formulation of this question.

Material and Methods
Prior approval of an Institutional Review Board (IRB) is required for all investigations involving human subjects and animals. Animal experimentation must be performed according to the Helsinki Declaration.

Study design: Provide a short survey of the tests or experiments. Include the independent variable(s) manipulated, the dependent variable(s) measured and all controls.

Methods: Describe methods and apparatus in detail. Provide references and brief description of methods already published. Identify drugs and chemicals, including generic name, dosage and administration. Describe the pre-study condition of patients or animals.

Analysis: Define the variables. Use statistical analysis that is appropriate for the study. Describe statistical methods used for each analysis; provide references for tests that are not well known.

Results
A concise report of important results only. Use figures and tables for the presentation of data; summarize the most important observations in the text. Start and end dates of the study must be indicated (from ... to, preferably exact dates, but at least months and year(s)).
Discussion
Summarize main results and make sure you can answer the question asked in the introduction, briefly supporting the answer with the relevant results. Explain and defend the answer, comment on contradictory or unexpected results and discrepancies with previous findings. Elaborate on new and important aspects of the study.

Acknowledgements
Use this section to name persons who have contributed to the article, but whose contributions do not justify authorship.

Footnotes
Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and Illustrations
Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and a figure legend, also prepared on a separate page. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Each illustration must be labelled with its number and the first author's name. B/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings of 800–1,200 dpi. Figure files must not be embedded in a document file but submitted separately (see detailed instructions at www.karger.com/res/).

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.00 per page.

References
In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharis TC, Boucher W, Spear K: Serum interleukin-6 reflects severity and mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

SI Units
Since the United States of America and other countries outside Europe where Respiration is read have not accepted the SI system, authors using SI units should add the conventional units in parentheses, for example: pO2 = 10 kPa (75 mm Hg).

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpg).

Page Charges
There are no page charges for papers of 4 or fewer print-ed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a page is equal to approx. 12 manuscript pages (including tables, illustrations and references).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3,000.00, which is a permissible cost of grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/policy.htm

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher's copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copying and design improvements as well as citation links.

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

E-publish
All articles are published electronically ahead of print with a DOI number and are supplemented later with the definite reference of the printed version. The articles become available immediately after the authors’ approval to publication, with the added advantage of being citable much earlier than in print. Authors can influence the time of appearance by promptly returning the proofs.

Reprints
Orders form and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

Financial Disclosure and Conflicts of Interest
Authors must disclose any and all financial involvement in any organization with a direct financial interest in the subject discussed in the submitted manuscript. Any conflict of interest for a given manuscript must be dealt with according to the statement of the International Committee of Medical Journal Editors (the ‘Vancouver Group’) (Lancet 1993;341:742).

Further Information
For any further details please contact the Editorial Department ‘Respiration’, Fax +41 61 306 14 34.
Contents

See the journal website for contents
One Gulf... One Air... One Breathe...

Gulf Thoracic

DUBAI 2015
4-7 MARCH
Grand Hyatt Hotel, Dubai, UAE

TOPICS INCLUDE:
- Asthma
- COPD
- Pulmonary Infections
- Interstitial Lung Diseases
- Pulmonary Hypertension
- Pleural Diseases
- Chest Imaging
- Sleep Medicine
- Critical Care Forum
- Interventional Pulmonology
- Respiratory Care
- Thoracic Oncology
- Thoracic Surgery
- Pediatric Pulmonology
- Research in Pulmonary Medicine
- Venous Thromboembolism

WORKSHOPS & COURSES:

30 CMEs

ORGANIZED BY:

IN COLLABORATION WITH:

WITH PARTICIPATION FROM:

OUR MAIN SPONSORS:

AstraZeneca
GlaxoSmithKline
Boehringer Ingelheim
MSD

Chiesi
Takeda
Novartis

www.gulfthoracic.com
ANNUAL CONGRESS SSAI-SGAI
IMPACT OF BASIC RESEARCH ON CLINICAL PRACTICE
Congress Center, Basel, 12–13 March 2015

Scientific Program

PLENARY LECTURES
Plenary Lecture 1:  
The impact of genomic sciences on medicine (Susan M. Gasser/Basel, CH)  
Plenary Lecture 2:  
Clinical impact of adult onset immunodeficiency (Hans Hartmut Peter/Freiburg, D)  
Plenary Lecture 3:  
Long-term single cell quantification: New tools for old questions (Timm Schroeder/Zurich, CH)

BASIC IMMUNOLOGY SYMPOSIA
Developmental Immunology  
Hans-Reimer Rodewald (Heidelberg, D); Meinrad Busslinger (Vienna, A); Thomas Boehm (Freiburg, D)  

Innate and Adaptive Immunity  
Andrew McKenzie (Cambridge, UK); William Agace (Lund, S); Hans-Georg Rammensee (Tübingen, D)  

Tolerance and Autoimmunity  
Ludger Klein (Munich, D); Adrian Liston (Leuven, B); Anne Cooke (Cambridge UK); Bruno Kyewski (Heidelberg, D)  

Infection and Immunity  
Peter Staeheli (Freiburg, D); Matteo Iannacone (Milan, I); Leo C. James (Cambridge, UK)

DIAGNOSTIC LABORATORY IMMUNOLOGY SYMPOSIUM
Nils Venhoff (Freiburg, D); Florian Deisenhammer (Innsbruck, A); Ulrich Sack (Leipzig, D)

CLINICAL IMMUNOLOGY SYMPOSIA
Therapy with Biologics  
Oliver Hausmann (Bern, CH); Gertjan Wolbink (Amsterdam, NL); Silja Bühler (Zurich, CH)  

Immunodeficiency Disorders  
Jana Pachlounik Schmid (Zurich, CH); Nathan Cantoni (Aarau, CH); Catharina Schütz (Ulm, D)  

Inflammation and Immunometabolism  
Marc Donath (Basel, CH); Christoph Hess (Basel, CH); Michael O. Hottiger (Zurich, CH)

ALLERGOLOGY SYMPOSIA
IgE in Allergic Diseases  
Menno C. Van Zelm (Rotterdam, NL); Harald Renz (Marburg, D); tba  

Vitamins and Trace Elements  
René Rizzoli (Geneva, CH); Mette Berger (Lausanne, CH); Ulrich Moser (Basel, CH)  

Vaccination and Immunotherapy  
Antonio Lanzavecchia (Bellinzona, CH); Alfred Zippelius (Basel, CH); Cezmi A. Akdis (Davos Platz, CH)

AEROBIOLOGY SYMPOSUM  
David Basler (Basel, CH); Otmar Holdenrieder (Zurich, CH); Sereina Maibach (Bern, CH)

YOUNG INVESTIGATORS MEETING  
Antonio Curro (Bern, CH); Stuart Spencer (London, UK)

LUNCH SESSIONS: sponsored by the following companies  
ALK-Abello AG, MEDA Pharma GmbH, Mundipharma Medical Company, Novartis Pharma Schweiz AG

SOCIAL EVENT  
Dinner at the Restaurant «Rhypark», Thursday, March 12, 2015, 19.45 h
56. Kongress
der Deutschen Gesellschaft für
Pneumologie und Beatmungsmedizin e.V.

18. bis 21. März 2015
CityCube Berlin

„Gemeinsam für den Patienten“

Kongresspräsident:
Prof. Dr. med. Torsten T. Bauer
Klinik für Pneumologie
Lungenklinik Heckeshorn
HELIOS Klinikum Emil von Behring
Walterhöferstraße 11
14165 Berlin
E-Mail: dgp2015@pneumologenkongress.de

Organisation:
Agentur KONSENS GmbH
Postfach 13 37
59356 Werne
Telefon: +49 (0) 23 89 / 52 75 0
E-Mail: dgp@agentur-konsens.de

www.dgp-kongress.de
Gemeinsame Jahresversammlung
Assemblée Annuelle Commune
Assemblea Annuale Comune

www.pneumo-congress.ch
16. – 17. April 2015
Palazzo dei Congressi Lugano
Hauptthemen der DGIM 2015

- Innovationen in Diagnostik und Therapie in der Inneren Medizin
  - Individualisierte Krebstherapie
  - Translationale Forschung
  - Renaissance der Immuntherapie
- Klinische Infektiologie
  - Mikrobiom
  - Multiresistente Erreger
- Palliativmedizin
- Internistische Intensivmedizin
- „Unterlassen“ als ärztliche Aufgabe
- Versorgung von chronischen, komplexen Erkrankungen als internistische Kernaufgabe
  - Alternsforschung und Geriatrie
  - Neue Aspekte zur Adipositas
  - Behandlung struktureller Herzerkrankungen

Kongress-Präsident
Prof. Dr. med. Michael Hallek,
Direktor der Klinik I für Innere Medizin,
Universitätsklinikum Köln (AöR)

Kongress-Agentur
m:con - manheim:congress GmbH

Hauptsponsor
Springer Medizin
Lectures Confirmed

ALAIN DE WECK HONORARY LECTURE
Lanny Rosenwasser “Asthma and obesity: Cytokines and adipokines”
ALBERT OEHLING HONORARY LECTURE
Ignacio Ansotegui “Role of molecular-based allergy diagnostics in asthma”
WILLIAM FRANKLAND HONORARY LECTURE
Stephen Holgate “Asthma subphenotypes across the life course”
LEONARD NOON and JOHN FREEMAN HONORARY LECTURE
Walter Canonica “New and future treatments for allergy & asthma”
CLEMENTS VON PIRQUET HONORARY LECTURE
Allen Kaplan “Asthma: the biochemical basis of phenotypic heterogeneity”
PAUL EHRLICH HONORARY LECTURE
Rudolf Valenta “Recombinant allergen-based approaches for diagnosis of allergic asthma”
FELICIDAD CUA LIM HONORARY LECTURE
Ruby Pawankar “Biodiversity, the microbiome and airways disease”

Congress Proceedings

Congress Proceedings will be published by the Medimond S.r.l – Monduzzi Editore International Proceedings Division. Such a publication will not only increase the success of the individual presentations and the Forum in general, but will also help to publicize the contents of the Forum to a much wider audience.

The Volume is ISBN coded and indexed in Conference Proceedings Citation Index published by Thomson Reuters – Philadelphia formerly Institute for Scientific Information ISI.

Invitations to contribute to the Proceedings Book will be e-mailed to those congress attendees whose abstracts are accepted either for oral or poster presentation.

CME credits

CME credits will be available for the VIII WORLD ASTHMA, ALLERGY & COPD FORUM participants. This Congress will be accredited by the European Accreditation Council for Continuing Medical Education (EACCME). Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credit.

Information on the process to convert the European Accreditation Council for Continuing Medical Education (EACCME) credit to American Medical Association (AMA) credit can be found at: www.ama-assn.org/go/internationalcme

www.wipocis.org
E-mail: info@wipocis.org, wipocis@mail.ru; Tel: +7-495-735-1414
**23rd European Conference on General Thoracic Surgery**  
31 May - 3 June 2015, Lisbon, Portugal

### Symposium for Nurses
- Lung transplant, thoracic trauma, palliative care, pulmonary rehabilitation

### 7th Collaborative Postgraduate Symposium on General Thoracic Surgery
- Teams from Europe, the Americas (North and South) and Asia competing for the Masters Cup

### Breakfast Sessions
**Sunday 31 May 2015: How to do it**
- VATS anatomical segmentectomy
- Oesocoloplasty: when and how
- Vascular access for ECMO: tips and tricks

**Monday 1 June 2015: State of the Art**
- Neonatal thoracic emergencies in thoracic surgery
- Diaphragmatic stimulation
- Contemporary modalities of radiation therapy: what the surgeon should know!

**Tuesday 2 June 2015: Debate**
- VATS lobectomy: this is the optimal access
  - Uniportal access
  - Multiportal access
- Parapneumonic Empyema
  - Early VATS debridement
  - Fibrinolytic therapy
- Surgical treatment for Mesothelioma
  - Extended pleuro-pneumonectomy
  - Decortication

### Joint ESTS-EACTA Session
- Thoracic surgeons and anaesthesiologists: face-to-face discussion

### Joint ESTS-STS Session

### VATS/RATS Session
- Pros and cons of each technique

### ESTS School at the Congress: hands-on sessions

<table>
<thead>
<tr>
<th>Database and Quality Certification Session</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Junior Lunch Symposium</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Joint Pediatric Congenital Thoracic Malformations</th>
</tr>
</thead>
</table>
- Treatment of long gap esophageal atresia
- Fetoscopic trachea balloon occlusion
- Pectus UP
- Cystic adenomatoid malformation: diagnosis and treatment
- Pediatric thoracic imaging interesting to thoracic surgeons

### ESTS Biology Club

<table>
<thead>
<tr>
<th>Joint ESTS-Portuguese-Brazilian Session</th>
</tr>
</thead>
</table>
- Implementation “ab initio” of VATS lobectomy program.
- An alternative for the treatment of severe pulmonary emphysema
- Living donor lung transplant
- Mediastinal staging methods in lung cancer
- Pancoast tumor – a surgical challenge? One center’s experience

### Joint ESTS-IASLC Session

<table>
<thead>
<tr>
<th>Joint ESTS-Chinese Association of Thoracic Surgeons Symposium</th>
</tr>
</thead>
</table>
- Thoracic surgery in China: Current status & future prospects

### SCIENTIFIC SECRETARIAT

**European Society of Thoracic Surgeons**  
1 The Quadrant, Wonford Road,  
Exeter EX2 4LE, UK  
Tel.: +44 1392 430671  
Fax.: +44 1392 430671  
sue@ests.org.uk  
www.ests.org

### OFFICIAL PCO REGISTRATION & ACCOMMODATION

**Leading**  
Rua Diogo do Couto 1B,  
2799–537, Linda-a-Velha, Portugal  
Tel.: +351 217 712 634  
Fax.: +351 217 712 629  
estss2015@leading.pt

### DEADLINE FOR EARLY REGISTRATION: 20 April 2015

For registration and information please visit  
www.estsmeetings.org/2015
Visit the website for more information

www.eaaci2015.com #eaaci2015
Pneumo Update Europe 2015

2nd European Update Congress in Pneumology
Budapest, 19 – 20 June 2015

- Complete medical field in two days
- Cutting-edge study results
- Ensured practical relevance

Submit an ePoster
Save 200 €

Scientific board
Roland Buhl (Germany)
David M. G. Halpin (UK)
Marc Humbert (France)
Walter McNicholas (Ireland)

Registration and further information
www.pneumo-update-europe.eu

Pulmonary Vascular Diseases
Marc Humbert (France)

Interstitial Lung Diseases
Luca Richeldi (UK)

Asthma
Roland Buhl (Germany)

Allergy
N.N.

COPD
David M. G. Halpin (UK)

Sleep Disordered Breathing
Walter McNicholas (Ireland)

Hot Topic: The future of personalized medicine
Peter J. Sterk (Netherlands)

Thoracic Surgery & Lung Transplantation
Gilbert Massard (France)

Pleural Disease
Julius Janssen (Netherlands)

Oncology
Johan Vansteenkiste (Belgium)

Pneumonia
Mark Woodhead (UK)

Pulmonary Endoscopy
Felix Herth (Germany)

Acute Respiratory Failure & Critical Care
Paolo Pelosi (Italy)

Tuberculosis & Infection
Christoph Lange (Germany)
Contact Info:
CIPP XIV Secretariat
27 rue Massena
06000 Nice
Tel. + 33 4 97 03 85 97
cipp@cipp-meeting.com

Website:
www.cipp-meeting.org
The *Journal of Innate Immunity* is a bimonthly journal covering all aspects within the area of innate immunity, including evolution of the immune system, molecular biology of cells involved in innate immunity, pattern recognition and signals of ‘danger’, microbial corruption, host response and inflammation, mucosal immunity, complement and coagulation, sepsis and septic shock, molecular genomics, and development of immunotherapies. The journal publishes original research articles, short communications and reviews.

**Selected contributions**

- **The Meta-Genome of Sepsis: Host Genetics, Pathogens and the Acute Immune Response:** Boyd, J.H.; Russell, J.A.; Fjell, C.D. (Vancouver, B.C.)
- **Mast Cell-Deficient Kit-w Mice Develop House Dust Mite-Induced Lung Inflammation despite Impaired Eosinophil Recruitment:** de Boer, J.D.; Yang, J.; van den Boogaard, F.E.; Hoogendijk, A.J.; de Beer, R.; van der Zee, J.S.; Roelofs, J.J.T.H.; van 't Veer, C.; de Vos, A.F.; van der Poll, T. (Amsterdam)
- **Mycobacterium tuberculosis-Induced Neutrophil Extracellular Traps Activate Human Macrophages:** Braian, C.; Hogeia, V.; Stendahl, O. (Linköping)
- **Antimicrobial Autophagy: A Conserved Innate Immune Response in Drosophila:** Moy, R.H.; Cherry, S. (Philadelphia, Pa.)
- **Control of Myeloid Cell Trafficking in Resolution:** Norling, L.V.; Perretti, M. (London)
- **Cystic Fibrosis Transmembrane Conductance Regulator Recruitment to Phagosomes in Neutrophils:** Zhou, Y.; Song, K.; Painter, R.G.; Aiken, M. (New Orleans, La.)
- **Identification of Infection- and Defense-Related Genes via a Dynamic Host-Pathogen Interaction Network Using a Candida Albicans-Zebrafish Infection Model:** Kuo, Z.-Y.; Chuang, Y.-Y.; Chao, C.-C.; Liu, F.-C.; Lan, C.-Y.; Chen, B.-S. (Shanghai)
- **Systems Biology of Circadian-Immune Interactions:** Mavroudis, P.D.; Scheff, J.D. (Piscataway, N.J.); Calvano, S.E. (New Brunswick, N.J.); Androulakis, I.P. (Piscataway, N.J./New Brunswick, N.J.)

**Journal of Innate Immunity**

- Founded: 2008
- Category: Basic and Clinical Research
- Field of Interest: Immunology
- Listed in bibliographic services, including PubMed/MEDLINE, Web of Science
- 2015: Volume 7
  - 6 issues per volume
  - Language: English
  - ISSN 1662–811X
  - e-ISSN 1662–8128

**Impact Factor 4.557**

More information at [www.karger.com/jin](http://www.karger.com/jin)
This high-yield reference book focuses on the clinical, technical, and pathological aspects of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). Its reviews cover all aspects of EBUS-TBNA, including the clinical perspective, technical aspects of the procedure, and cytomorphology of common and uncommon entities, as well as highlights diagnostic challenges. Each chapter features a multitude of full-color high-resolution images and includes key references to the current literature in the field. Additionally, reference tables and informative figures highlight the salient points. The book is unique in that it is written by experienced thoracic surgeons, pulmonary medicine physicians, and cytopathologists who use EBUS-TBNA in a large medical center.

This publication is of interest to individuals learning and practicing cytopathology, in addition to clinicians practicing pulmonary/thoracic medicine and surgeons. In short, it provides important pearls of wisdom to create a comprehensive reference for all physicians involved with EBUS-TBNA.
The Tobacco Epidemic
2nd revised and extended edition

Editors
R. Loddenkemper (Berlin)
M. Kreuter (Heidelberg)

Preliminary Contents

- History of Tobacco Production and Use: Hanafin, J.; Clancy L.
- Global Tobacco Epidemic: Mackay, J.; Schluger, N.
- Strategy of the Tobacco Industry to Keep the Tobacco Epidemic Going: Weishaar, H.
- Chemistry and Primary Toxicity of Tobacco and Tobacco Smoke: Wiebel, F.
- Nicotine Dependence: Zaveri, N.; Rollema, H.; Swan, G.E.
- The Psychology of the Smoker: Gilbert, D.G.; Pergadia, M.L.
- Respiratory Disorders Related to Smoking Tobacco: Murray, J.F.; Buist, A.S.
- Cardiac and Other Disorders Related to Smoking Tobacco: Barnoya, J.
- Health Effects of Passive Smoking in Children: Bush, A.
- Health Effects of Passive Smoking in Adults: Kabir, Z.; Clancy, L.
- Economics of Tobacco Use and Control: Townsend, J.
- Legislation and Smoking Prevention: Latif, E.; Warner, V.
- Youth and Tobacco: Bauern-Kemény; Kreuter, M.
- Impact of Media, Movies and TV on Tobacco Use in the Youth: Sargent, J.D.; Hanewinkel, R.
- Social Determinants of Cigarette Smoking: Upson, D.
- Smoking and Mental Health: Caillé-Garnier, S.; Baker, A.L.; Todd, J.; Turner, A.; Dayas, C.
- Patterns and Predictors of Smoking Cessation: Ditre, J.W.; Zale, E.L.; Brandon, T.H.
- Smoking Cessation: The Role of Health Care Professionals: Leone, F.T.
- Pharmacotherapy: Nicotine Replacement and other Drugs in Smoking Cessation (including vaccination): Tønnessen, P.
- Smokeless Tobacco – Health Hazards or less Harm?: Bolinder, G.; Gilljam, J.
- Waterpipe Tobacco Smoking – A less Harmful Alternative?: Jawad, M.
- E-Cigarettes: The Issues behind the Moral Quandary: Vardavas, C.
Editor's Note

1 The Forgotten Species
Herth, F.J.F. (Heidelberg)

Thematic Review Series Vol. 89, 2015

2 Principles of Rehabilitation and Reactivation

Editorial Comments

12 Is Endoscopic Lung Volume Reduction Able to Reverse Pulmonary Hypertension in Patients with Severe Emphysema?
Bugalho, A. (Loures/Lisbon)

15 Digging into ‘the Rabbit-Hole’ of the Extracellular Matrix
Burgstaller, G. (Munich)

17 Bronchoscope: Beyond the Thorax!
Gasparini, S.; Bonifazi, M. (Ancona)

Clinical Investigations

19 A Comparative Study of Bronchoscopic Microsample Probe versus Bronchoalveolar Lavage in Patients with Burns-Related Inhalational Injury, Acute Lung Injury and Chronic Stable Lung Disease

27 Decline in Asthma Prevalence and Severity in Israel over a 10-Year Period
Cohen, S.; Berkman, N.; Avital, A.; Springer, C.; Kordoba, L.; Haklai, Z. (Jerusalem); Eshel, A. (Tel Aviv); Goldberg, S.; Picard, E. (Jerusalem)

33 Association of Lifestyle and Cardiovascular Risk Factors with Lung Function in a Sample of the Adult Italian Population: A Cross-Sectional Survey
Laurendi, G.; Donfrancesco, C.; Palmieri, L. (Rome); Vanuzzo, D. (Florence); Scalera, G.; Giampaoli, S. (Rome) on behalf of the Osservatorio Epidemiologico Cardiovascolare/Health Examination Survey 2008–2012

Interventional Pulmonology

41 Endoscopic Lung Volume Reduction with Endobronchial Valves in Patients with Severe Emphysema and Established Pulmonary Hypertension

49 Fully Covered Self-Expandable Metal Stent in Tracheobronchial Disorders: Clinical Experience
Marchese, R.; Poidomani, G.; Paglino, G. (Palermo); Crimi, C. (Catania); Lo Negro, C.; Argano, V. (Palermo)

Novel Insights from Clinical Practice

57 Left Adrenal Biopsy Using the Convex Curvilinear Ultrasound Scope

62 Successful Early Rituximab Treatment in a Case of Systemic Lupus Erythematosus with Potentially Fatal Diffuse Alveolar Hemorrhage

Reviews

66 Current Perspectives on the Contribution of Inhaled Corticosteroids to an Increased Risk for Diabetes Onset and Progression in Patients with Chronic Obstructive Pulmonary Disease
Herth, F.J.F. (Heidelberg); Bramlage, P. (Mahlow); Müller-Wieland, D. (Hamburg)

76 Segmental Approach to Lung Volume Reduction Therapy for Emphysema Patients

82 From Breathing to Respiration
Fitting, J.-W. (Lausanne)

Letter to the Editor

88 Autobullectomy in Patients with COPD
van Geffen, W.H.; Slebos, D.-J. (Groningen)

Cover Illustration